Identifai Genetics Analytic Validity Study - Compound Heterozygosity and Samples Collection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-05

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate a noninvasive prenatal diagnosis procedure for genetic conditions in the developing fetus by analyzing fetal genetic material present in the pregnant mother's blood.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prenatal Microarray Follow-Up Study

NCT02160938

Genetic Diseases

COMPLETED

Evaluating Prenatal Exome Sequencing Study

NCT05290701

Congenital Anomalies Mendelian Disorders Genetic Diseases, Inborn

ACTIVE_NOT_RECRUITING

Study of Gene Associations and Infertility

NCT01223092

Infertility

ENROLLING_BY_INVITATION

Child Development and Genetic Biomarkers(II): Gene Verification and Data Integration

NCT06532721

Developmental Disabilities

RECRUITING

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

NCT01375543

Genetic Predisposition

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Amniocentesis (drawing fluid from inside the womb) and chorionic villus sampling (removing a very small amount of the developing placenta) are the current "gold standard" for diagnosis of genetic abnormalities in the developing fetus (unborn child) during the pregnancy. However, these procedures have small risks of miscarriage and are normally used for women with known risk factors for a genetic condition in the fetus. Finding a method to detect genetic changes in a fetus without performing a procedure associated with a risk for miscarriage may be helpful for the clinical care of pregnant patients in collaboration with their providers in the future.

It has been demonstrated that cell-free fetal (cff) DNA is present in the mother's bloodstream. This is already used to detect common conditions like Down Syndrome, a condition that all pregnancies are at risk for. The existing cffDNA tests are not currently able to detect if a fetus is a carrier or affected with the conditions parents are commonly screened for using carrier screening and other genomic tests. The study aim to test the use of new genetic techniques on cffDNA that can find if a fetus is affected with condition that one or both parents are carriers for. The study also aim to investigate if these new tools can detect other spontaneous and inherited genetic changes. This will make prenatal detection possible of many more genetic disorders than can currently be done by drawing blood from the mother. The Maternal and Paternal blood samples will be also used for the development of new methods to detect genetic abnormalities in the developing fetus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prenatal Diagnosis Genetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Patient information is confidential and shared exclusively with the treating physician

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Identifai Genetics Analytic Validity - Compound Heterozygosity and Samples Collection

Group Type EXPERIMENTAL

Non Invasive Prenatal Test via blood sample

Intervention Type OTHER

Maternal - blood draw, Paternal - blood draw/Saliva sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non Invasive Prenatal Test via blood sample

Maternal - blood draw, Paternal - blood draw/Saliva sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

General:

* Parental age≥18
* Singleton pregnancy
* Willingness and ability to provide informed consent to participate in study
* Patient having a diagnostic procedure (CVS, amniocentesis, cordocentesis) or delivering on site (obtain cord blood/cord segment)

Main Study:

* Gestational age: 10-23 weeks
* Parents are both carriers of different known pathogenic SNVs or short indels (\<=5bp) in the same gene (compound heterozygosity).

Substudy:

* Gestational age ≥10 weeks
* Either parent or both carry a known structural variant and/or other chromosomal anomalies AND/OR Ultrasound highly suggestive of an underlying genetic aberration (e.g., cardiac outlet and 22q)